1. Home
  2. GNPX vs ULY Comparison

GNPX vs ULY Comparison

Compare GNPX & ULY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNPX
  • ULY
  • Stock Information
  • Founded
  • GNPX 2009
  • ULY 2013
  • Country
  • GNPX United States
  • ULY United States
  • Employees
  • GNPX N/A
  • ULY N/A
  • Industry
  • GNPX Biotechnology: Pharmaceutical Preparations
  • ULY
  • Sector
  • GNPX Health Care
  • ULY
  • Exchange
  • GNPX Nasdaq
  • ULY Nasdaq
  • Market Cap
  • GNPX 7.5M
  • ULY 7.4M
  • IPO Year
  • GNPX 2018
  • ULY N/A
  • Fundamental
  • Price
  • GNPX $0.29
  • ULY $4.67
  • Analyst Decision
  • GNPX
  • ULY Strong Buy
  • Analyst Count
  • GNPX 0
  • ULY 1
  • Target Price
  • GNPX N/A
  • ULY $12.00
  • AVG Volume (30 Days)
  • GNPX 1.8M
  • ULY 33.2K
  • Earning Date
  • GNPX 05-12-2025
  • ULY 05-13-2025
  • Dividend Yield
  • GNPX N/A
  • ULY N/A
  • EPS Growth
  • GNPX N/A
  • ULY N/A
  • EPS
  • GNPX N/A
  • ULY N/A
  • Revenue
  • GNPX N/A
  • ULY $134,085,000.00
  • Revenue This Year
  • GNPX N/A
  • ULY N/A
  • Revenue Next Year
  • GNPX N/A
  • ULY $23.08
  • P/E Ratio
  • GNPX N/A
  • ULY N/A
  • Revenue Growth
  • GNPX N/A
  • ULY N/A
  • 52 Week Low
  • GNPX $0.22
  • ULY $2.99
  • 52 Week High
  • GNPX $3.97
  • ULY $23.52
  • Technical
  • Relative Strength Index (RSI)
  • GNPX 50.37
  • ULY 35.73
  • Support Level
  • GNPX $0.26
  • ULY $5.01
  • Resistance Level
  • GNPX $0.37
  • ULY $5.77
  • Average True Range (ATR)
  • GNPX 0.04
  • ULY 0.56
  • MACD
  • GNPX 0.00
  • ULY -0.29
  • Stochastic Oscillator
  • GNPX 35.04
  • ULY 0.23

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About ULY Urgent.ly Inc.

Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.

Share on Social Networks: